← All candidates
81 insider filings on record.
81 filings on record.
NAMSWNewAmsterdam Pharma Co N.V.
NasdaqGM
$11.78
+0.00% · Sep 11
81 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 1 buy● 29 sells◆ 3 8-K
▸ hover a marker for the filing · drag to zoom · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Float
80.7M
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Topper James N
Bought $167.4K on Jun 16 — 8,584 sh @ $19.50, held indirect, 0.3% of their stake.
1 of 1 position beat the S&P
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
76 more transactions on Pro →Context
Coverage
A Look At NewAmsterdam Pharma (NAMS) Valuation After Recent Share Price WeaknessSimply Wall St. · 06-11NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesSimply Wall St. · 05-11Do NewAmsterdam Pharma’s (NAMS) Dilution Plans Reframe Its Path to Funding Ongoing Losses?Simply Wall St. · 05-08NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded TrendsMarketBeat · 05-08
The file stays open
81 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice